Side effects and quality of life after inadvertent radiation overdosage in brachytherapy of head-and-neck cancer

被引:13
作者
Evensen, JF [1 ]
Bjordal, K
Knutsen, BH
Olsen, DR
Store, G
Tausjo, JE
机构
[1] Norwegian Radium Hosp, Dept Med Oncol & Radiotherapy, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Dept Med Phys, N-0310 Oslo, Norway
[3] Univ Oslo, Natl Hosp, Dept Maxillofacial Surg, Oslo, Norway
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2002年 / 52卷 / 04期
关键词
brachytherapy; overdosage; quality of life; side effects; EORTC QLQ-C30; EORTC QLQH&N35;
D O I
10.1016/S0360-3016(01)02726-2
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: By comparing our old (DP5, in use from 1978 to 1994) and new (Plato, Nucletron) dose planning system, we found that the old system underestimated doses by 20-25%. To study the possible consequences for the patients treated between 1978 and 1994, all who were still alive were invited to undergo an examination with respect to side effects and quality of life (QOL). Methods and Materials: The degree of overdosage was calculated by comparing the isodose distribution generated on the two dose planning systems. Eighty-four patients were then invited to undergo an examination with respect to side effects and QOL. The side effects were scored according to the LENT SOMA system and QOL according to European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30), and EORTC Quality of Life Questionnaire-Head & Neck 35 (QLQH&N35). Results: The mean overdosage of brachytherapy was 19.3%. No association was found between overdosage and side effects or QOL. For implants in the lateral border of the tongue, we found a statistically significant correlation between osteoradionecrosis and the following parameters: linear activity, total activity, dose rate, and extrapolated response dose. By multivariate analysis, only total implanted activity and the use of lead protection during brachytherapy were found to be of prognostic significance with respect to development of osteoradionecrosis. Conclusion: The incidence of side effects after brachytherapy at the Norwegian Radium Hospital seems to have been somewhat higher in the period under investigation than at other institutions. There may be several explanations, including the use of external beam radiotherapy before brachytherapy and departure from the Paris system among others. However, the side effects were not associated with the overdosage that was the basis for the study. As opposed to the general consensus of opinion, long-term QOL was found to be worse after brachytherapy than after external beam radiotherapy. This calls for increased awareness and a systematic prospective registration of the long-term side effects of brachytherapy. (C) 2002 Elsevier Science Inc.
引用
收藏
页码:944 / 952
页数:9
相关论文
共 18 条
[11]   DOSE AND DOSE-RATE IN IR-192 INTERSTITIAL IRRADIATION FOR CARCINOMA OF TONGUE [J].
INOUE, T ;
HORI, S ;
MIYATA, Y ;
IKEDA, H ;
SHIGEMATSU, Y ;
FUCHIHATA, H ;
TANAKA, Y .
ACTA RADIOLOGICA-THERAPY PHYSICS BIOLOGY, 1978, 17 (01) :27-32
[12]   Analysis of risk factors for mandibular bone radionecrosis after exclusive low dose-rate brachytherapy for oral cancer [J].
Lozza, L ;
Cerrotta, A ;
Gardani, G ;
DeMarie, M ;
DiRusso, A ;
Kenda, R ;
Tana, S ;
Valvo, F ;
Zucali, R .
RADIOTHERAPY AND ONCOLOGY, 1997, 44 (02) :143-147
[13]   EFFECT OF DOSE-RATE ON LOCAL-CONTROL AND COMPLICATIONS IN DEFINITIVE IRRADIATION OF T1-2 SQUAMOUS-CELL CARCINOMAS OF MOBILE TONGUE AND FLOOR OF MOUTH WITH INTERSTITIAL IR-192 [J].
MAZERON, JJ ;
SIMON, JM ;
LEPECHOUX, C ;
CROOK, JM ;
GRIMARD, L ;
PIEDBOIS, P ;
LEBOURGEOIS, JP ;
PIERQUIN, B .
RADIOTHERAPY AND ONCOLOGY, 1991, 21 (01) :39-47
[14]   IR-192 IMPLANTATION OF T1-CARCINOMAS AND T2-CARCINOMAS OF THE MOBILE TONGUE [J].
MAZERON, JJ ;
CROOK, JM ;
BENCK, V ;
MARINELLO, G ;
MARTIN, M ;
RAYNAL, M ;
HADDAD, E ;
PEYNEGRE, R ;
LEBOURGEOIS, JP ;
WALOP, W ;
PIERQUIN, B .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 19 (06) :1369-1376
[15]   ABOUT TOLERANCE AND QUALITY - AN IMPORTANT NOTICE TO ALL RADIATION ONCOLOGISTS [J].
OVERGAARD, J ;
BARTELINK, H .
RADIOTHERAPY AND ONCOLOGY, 1995, 35 (01) :1-3
[16]   PARIS SYSTEM IN INTERSTITIAL RADIATION-THERAPY [J].
PIERQUIN, B ;
DUTREIX, A ;
PAINE, CH ;
CHASSAGNE, D ;
MARINELLO, G ;
ASH, D .
ACTA RADIOLOGICA-THERAPY PHYSICS BIOLOGY, 1978, 17 (01) :33-48
[17]   CHANGING ASPECTS IN THE TREATMENT OF SQUAMOUS-CELL CARCINOMA OF THE ORAL TONGUE [J].
VERMUND, H ;
JACOBSEN, AB ;
KAALHUS, O ;
LEVERNES, S ;
MELSOM, H ;
TAUSJO, J ;
THORUD, E ;
THORVIK, J ;
WINTHER, F ;
WIST, E .
ACTA ONCOLOGICA, 1987, 26 (03) :163-172
[18]   PRIMARY RADIOTHERAPY IN THE TREATMENT OF STAGE-I AND STAGE-II ORAL TONGUE CANCERS - IMPORTANCE OF THE PROPORTION OF THERAPY DELIVERED WITH INTERSTITIAL THERAPY [J].
WENDT, CD ;
PETERS, LJ ;
DELCLOS, L ;
ANG, KK ;
MORRISON, WH ;
MAOR, MH ;
ROBBINS, KT ;
BYERS, RM ;
CARLSON, LS ;
OSWALD, MJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1990, 18 (06) :1287-1292